ERGO Share Price Performance
Recent ERGO News & Updates
No updates
Ergomed plc Key Details
Last Reported Earnings
Jun 30, 2023
Next Reporting Earnings
n/a
- Earnings per share (EPS)
- 0.29
- Gross Margin
- 54.75%
- Net Profit Margin
- 9.86%
- Debt/Equity Ratio
- 0%
Ergomed plc Competitors
About ERGO
- Founded
- 1997
- Employees
- 1400
- CEO
- WebsiteView website
Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom, rest of Europe, the Middle East, Africa, North America, and internationally. The company operates through two segments, Clinical Research Services and Pharmacovigilance. It provides and manages clinical development, trial management, and pharmacovigilance services for pharmaceutical, biotechnology, and generics companies. The company focuses on various therapeutic areas, including oncology, hematology, allergy, respiratory, and neurology/CNS, as well as develops orphan drugs. It also provides site support services. The company was formerly known as Ergomed Clinical Research Limited and changed its name to Ergomed plc in June 2014. Ergomed plc was founded in 1997 and is headquartered in Guildford, the United Kingdom.
U.K. Market Performance
- 7 Days: 2.1%
- 3 Months: 8.5%
- 1 Year: 8.4%
- Year to Date: 9.0%
Over the past 7 days, the market has risen 2.1% with the Consumer Staples sector contributing the most to the gain. As for the past 12 months, the market is up 8.4%. Earnings are forecast to grow by 15% annually. Market details ›
Companies across the globe are beginning to pay attention to agentic AI. It’s also a term you’re likely to hear a lot during earnings season. In fact, it came up 26 times during...
Continue reading